Literature DB >> 9521692

Evidence for lipid-dependent structural changes in specific domains of apolipoprotein B100.

V Chauhan1, X Wang, T Ramsamy, R W Milne, D L Sparks.   

Abstract

The structural organization and stability of apoB100 in complexes containing triglyceride (TG) and phospholipid have been examined. LDL was delipidated to form aqueous soluble apoB100-TG complexes that retain approximately 70% of LDL TG, but contain no other lipids. The apoB100-TG complexes exhibited reduced amphipathic alpha-helical content (17%) and net negative charge (-2.9 mV) as compared to native LDL-apoB100 (49% and -6 mV, respectively). Of 28 anti-apoB monoclonal antibodies tested, 15 showed partial or full reactivity with apoB100-TG. The immunoreactive epitopes of apoB100-TG were restricted to those situated in either the amino terminal globular domain (4 of 6) or in regions of apoB100 that are predicted to be composed of amphipathic beta-strands (11 of 13). Incubation of the apoB100-TG complex with palmitoyloleoylphosphatidylcholine (POPC) spontaneously (< 10 min) formed homogeneous lipoproteins (20 nm) that contained approximately 300 molecules of POPC per particle (apoB100-PC). Phospholipidation of apoB100-TG complexes partially recovered the alpha-helical content (34%) and net negative charge (-4.9 mV) of the native LDL and restored resistance of apoB100 to denaturation by guanidine HCl (5.8 M). Addition of phospholipids to apoB100-TG also increased the immunoreactivity of specific epitopes that are located primarily in regions of apoB100 that are thought to be constituted of amphipathic beta-strands. The effects of TG and phospholipid on apoB100 conformation appear to be highly domain-specific. On the basis of these results, we propose that the beta-strands of apoB100 may represent a nonflexible lipid-associating backbone, while the amphipathic alpha-helical domains may represent flexible lipid-binding regions that allow the particle to accommodate varying amounts of lipid.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521692     DOI: 10.1021/bi9718853

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  4 in total

1.  Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation.

Authors:  Su Duy Nguyen; Matti Javanainen; Sami Rissanen; Hongxia Zhao; Jenni Huusko; Annukka M Kivelä; Seppo Ylä-Herttuala; Mohamad Navab; Alan M Fogelman; Ilpo Vattulainen; Petri T Kovanen; Katariina Öörni
Journal:  J Lipid Res       Date:  2015-04-10       Impact factor: 5.922

Review 2.  Apolipoproteins and amyloid fibril formation in atherosclerosis.

Authors:  Chai Lean Teoh; Michael D W Griffin; Geoffrey J Howlett
Journal:  Protein Cell       Date:  2011-03-12       Impact factor: 14.870

Review 3.  Apolipoprotein A-IV: a protein intimately involved in metabolism.

Authors:  Fei Wang; Alison B Kohan; Chun-Min Lo; Min Liu; Philip Howles; Patrick Tso
Journal:  J Lipid Res       Date:  2015-02-01       Impact factor: 5.922

4.  Dimyristoylphosphotidylcholine induces conformational changes in apoB that lowers lipoprotein(a).

Authors:  Yan-Ting Wang; Anne von Zychlinski; Sally P A McCormick
Journal:  J Lipid Res       Date:  2008-12-19       Impact factor: 5.922

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.